Genematrix Inc.
KKRX:1098201,491.00
KRW
+16.00
(+1.08%)
ISIN
KR7109820001
Return %
Stock
S&P 500
1Y
-40.95
13.14
3Y
-39.14
80.78
5Y
-84.66
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Soo-Ok Kim
- Full Time Employees
- 69
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Seongnam-si South Korea
- IPO Date
- Nov 10, 2009
- Website
- genematrix.net
- Similar Companies
- Business
- Genematrix Inc. is a South Korea-based biotechnology company that specializes in the research, development, and commercialization of multiplex molecular diagnostics, in vitro diagnostic (IVD) medical devices, and novel therapeutic vaccines. Founded in 2000 and headquartered in Seongnam, South Korea, the company operates primarily within the healthcare and life sciences sectors, providing clinical laboratories, hospitals, research institutions, and healthcare providers globally with genetic analysis and disease screening solutions. The company's core product and service portfolio includes proprietary multiplex real-time PCR diagnostic assays marketed under the NeoPlex brand for the simultaneous detection of respiratory tract infections, sexually transmitted infections (STIs), human papillomavirus (HPV) genotyping, gastrointestinal pathogens, tuberculosis and non-tuberculous mycobacteria, and poxviruses; proprietary diagnostic technology platforms such as C-Tag (multiplex real-time PCR tag technology), RFMP (Restriction Fragment Mass Polymorphism for mass spectrometry-based mutation analysis), TriO, and Encleap; OmniPlex multiplex bead-based suspension array systems for high-throughput target detection; clinical chemistry and biochemical diagnostic reagents, automated analyzers, calibrators, and quality control materials; and contract research and genetic testing services for clinical and academic applications. In addition to diagnostics, Genematrix develops biopharmaceutical therapeutics and vaccines utilizing its proprietary chimeric adenovirus vector platform (GM-ChimAd), advancing preclinical and clinical pipelines that include candidates for herpes zoster (GM-ChimAd-HZ), Hepatitis A (GMAI-02), and HPV-related cervical cancer. In recent developments, Genematrix has expanded its international regulatory compliance and commercial footprint by obtaining European In Vitro Diagnostic Medical Devices Regulation (CE-IVDR) certifications for its flagship NeoPlex multiplex molecular diagnostic line, including CE-IVDR registration for its NeoPlex TB/NTM-5 Detection kit and associated diagnostic analysis software. The company has advanced its clinical development pipeline by securing Investigational New Drug (IND) approval to commence Phase 1 clinical trials for its Hepatitis A vaccine candidate GMAI-02 and validating the heightened cellular immunogenicity of its GM-ChimAd-HZ shingles vaccine candidate in peer-reviewed preclinical studies. Genematrix has also strengthened its global intellectual property portfolio with patent allowances across the United States, Europe, and South Korea covering target nucleic acid detection and chimeric adenoviral vaccine platforms, while participating in government-backed national projects for poxvirus vaccine development and export acceleration under South Korea's Global Small Giant initiative.